SMN2 (SMN2 variant d) as a potential drug target and biomarker for neurodegenerative diseases

Target Name: SMN2

NCBI ID: G6607

SMN2

SMN2 (SMN2 variant d) as a potential drug target and biomarker for neurodegenerative diseases

Abstract:
SMN2 (SMN2 variant d) is a variant form of the neurotrophic factor 2 (SMN2) gene, which is the most important gene in spinal cord anterior horn neurons (CNS neurons). Mutated forms of the SMN2 gene are associated with many neurodegenerative diseases, such as Parkinson's disease, Alzheimer's disease, and amyotrophic lateral sclerosis (ALS). This article aims to explore the relationship between SMN2 gene variation and neurodegenerative diseases, and discuss the possibility of SMN2 as a potential drug target and biomarker.

introduction:
Neurodegenerative diseases are a complex group of disorders characterized by nerve cell death and damage, leading to decreased neurological function and severe illness. These diseases include Parkinson's disease, Alzheimer's disease, amyotrophic lateral sclerosis (ALS), multiple sclerosis, and others. Neurodegenerative diseases often cause patients to lose the ability to take care of themselves, and in severe cases, even lead to death. Therefore, studying the causes and treatments of neurodegenerative diseases has important clinical significance. In recent years, with the development of molecular biology, more and more studies have found that neurodegenerative diseases are closely related to genetic variations.

The relationship between SMN2 gene and neurodegenerative diseases:
The SMN2 gene is the most important gene in spinal cord anterior horn neurons (CNS neurons), encoding spinal motor neuron protein (SMN protein). SMN protein is a neurotrophic factor that is essential for the survival and function of neurons. Neurodegenerative diseases are closely related to mutated forms of the SMN2 gene.

Parkinson's disease is a neurodegenerative disease characterized by nigrostriatal degeneration, leading to the death of neurons at the striatal-motoneuron junction (SNh), resulting in reduced movement, muscle stiffness, and slowness of movement. People with Parkinson's disease often carry mutated forms of the SMN2 gene, which carry genetic mutations that lead to neuronal death and damage.

Alzheimer's disease is a form of dementia characterized by neuronal death and damage to neuronal connections, leading to cognitive decline and memory loss. People with Alzheimer's disease also carry mutated forms of the SMN2 gene.

Amyotrophic lateral sclerosis (ALS) is an inherited neurodegenerative disease characterized by neuronal death and damage to neuronal connections, leading to muscle atrophy and decreased strength. Amyotrophic lateral sclerosis (ALS) is closely related to mutated forms of the SMN2 gene.

Possibility of SMN2 gene as drug target and biomarker:
The mutated form of the SMN2 gene is closely related to neurodegenerative diseases. Therefore, the SMN2 gene has important clinical significance as a drug target and biomarker.

First, mutated forms of the SMN2 gene can serve as potential drug targets for the treatment of neurodegenerative diseases. By developing treatments that target mutated forms of the SMN2 gene, patients' quality of life and disease severity can be improved. For example, for patients with Parkinson's disease, mutated forms of the SMN2 gene can be used as drug targets to develop drugs that can delay neuron death and increase neuron survival time.

Secondly, the mutated form of the SMN2 gene can be used as a biomarker for the diagnosis of neurodegenerative diseases. By detecting mutated forms of the SMN2 gene, neurodegenerative diseases can be diagnosed and staged early. For example, for patients with Parkinson's disease, the mutated form of the SMN2 gene can be detected for early diagnosis and judgment of the severity of the disease.

in conclusion:
Mutated forms of the SMN2 gene are closely associated with neurodegenerative diseases. By developing therapeutics that target mutated forms of the SMN2 gene and as biomarkers for the diagnosis of neurodegenerative diseases, patients' quality of life and disease severity can be improved. Therefore, the mutated form of the SMN2 gene is a potential drug target and biomarker worthy of further research and development.

Protein Name: Survival Of Motor Neuron 2, Centromeric

Functions: The SMN complex catalyzes the assembly of small nuclear ribonucleoproteins (snRNPs), the building blocks of the spliceosome, and thereby plays an important role in the splicing of cellular pre-mRNAs (PubMed:9845364, PubMed:18984161). Most spliceosomal snRNPs contain a common set of Sm proteins SNRPB, SNRPD1, SNRPD2, SNRPD3, SNRPE, SNRPF and SNRPG that assemble in a heptameric protein ring on the Sm site of the small nuclear RNA to form the core snRNP (Sm core) (PubMed:18984161). In the cytosol, the Sm proteins SNRPD1, SNRPD2, SNRPE, SNRPF and SNRPG are trapped in an inactive 6S pICln-Sm complex by the chaperone CLNS1A that controls the assembly of the core snRNP (PubMed:18984161). To assemble core snRNPs, the SMN complex accepts the trapped 5Sm proteins from CLNS1A forming an intermediate (PubMed:18984161). Within the SMN complex, SMN1 acts as a structural backbone and together with GEMIN2 it gathers the Sm complex subunits (PubMed:21816274, PubMed:22101937, PubMed:17178713). Binding of snRNA inside 5Sm ultimately triggers eviction of the SMN complex, thereby allowing binding of SNRPD3 and SNRPB to complete assembly of the core snRNP (PubMed:31799625). Ensures the correct splicing of U12 intron-containing genes that may be important for normal motor and proprioceptive neurons development (PubMed:23063131). Also required for resolving RNA-DNA hybrids created by RNA polymerase II, that form R-loop in transcription terminal regions, an important step in proper transcription termination (PubMed:26700805). May also play a role in the metabolism of small nucleolar ribonucleoprotein (snoRNPs)

The "SMN2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SMN2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets